Holen Sie sich die Stockscreener-App
8.97
3.60%
-0.335
Vorhandelsmarkt:
8.90
-0.07
-0.78%
Schlusskurs vom Vortag:
$9.305
Offen:
$9.19
24-Stunden-Volumen:
1.75M
Relative Volume:
0.31
Marktkapitalisierung:
$700.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.96M
KGV:
-2.8386
EPS:
-3.16
Netto-Cashflow:
$-176.27M
1W Leistung:
-14.16%
1M Leistung:
+89.64%
6M Leistung:
-10.39%
1J Leistung:
-25.37%
1-Tages-Spanne:
$8.91
$9.41
1-Wochen-Bereich:
$8.255
$10.61
52-Wochen-Spanne:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Vergleichen Sie REPL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
8.97 | 726.31M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-09-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Replimune Group (NASDAQ:REPL) Stock Price Down 14.8%Should You Sell? - MarketBeat
Replimune Group Inc. stock volume spike explainedInsider Selling & Precise Buy Zone Tips - newser.com
Trend analysis for Replimune Group Inc. this week2025 Historical Comparison & AI Driven Stock Movement Reports - newser.com
What risks investors should watch in Replimune Group Inc. stockM&A Rumor & High Accuracy Swing Trade Signals - newser.com
BMO Capital Upgrades Replimune Group to Market Perform From Underperform, Adjusts Price Target to $11 From $2 - MarketScreener
BMO Capital Upgrades Replimune Group (REPL) - Nasdaq
Smart tools for monitoring Replimune Group Inc.’s price actionJuly 2025 Decliners & Long-Term Growth Plans - newser.com
REPL: Analyst Raises Price Target and Upgrades Rating to Market Perform | REPL Stock News - GuruFocus
Will Replimune Group Inc. stock benefit from AI adoptionRate Hike & Breakout Confirmation Alerts - newser.com
What recovery options are there for Replimune Group Inc.Market Trend Review & Community Verified Watchlist Alerts - newser.com
Price momentum metrics for Replimune Group Inc. explainedMarket Movement Recap & Safe Entry Momentum Tips - newser.com
How Replimune Group Inc. stock compares to growth peersPortfolio Update Report & Free Expert Verified Stock Movement Alerts - newser.com
Replimune stock rating upgraded by BMO Capital on improved FDA outlook - Investing.com Canada
What hedge fund activity signals for Replimune Group Inc. stockJuly 2025 WrapUp & Daily Volume Surge Trade Alerts - newser.com
How to use Fibonacci retracement on Replimune Group Inc.July 2025 Volume & Daily Stock Trend Watchlist - newser.com
How to build a custom watchlist for Replimune Group Inc.Insider Selling & Technical Pattern Based Buy Signals - newser.com
What to do if you’re stuck in Replimune Group Inc.Market Sentiment Summary & Daily Price Action Insights - newser.com
Is Replimune Group Inc. stock a buy before product launchesPortfolio Return Report & Community Trade Idea Sharing - newser.com
Why Replimune Group Inc. stock is a must watch in 2025Trade Signal Summary & Daily Profit Maximizing Tips - newser.com
Brokers Set Expectations for Replimune Group Q2 Earnings - MarketBeat
Replimune Group (NASDAQ:REPL) Stock Price Up 9.2% After Analyst Upgrade - MarketBeat
HC Wainwright Forecasts Replimune Group Q2 Earnings - MarketBeat
Replimune Group (REPL) Price Target Increased by 48.75% to 10.84 - Nasdaq
Traders Buy High Volume of Call Options on Replimune Group (NASDAQ:REPL) - MarketBeat
How Replimune Group Inc. stock reacts to Fed rate cuts2025 Year in Review & Fast Gaining Stock Reports - Fundação Cultural do Pará
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):